Stock Analysis
CareDx, Inc (CDNA) Stock Analysis
CareDx, Inc (CDNA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
CareDx, Inc (CDNA) currently has an AIQ Score of 59/100, indicating a neutral setup. Quality is the strongest factor at 92/100. Value is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
CDNA at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $70.74 |
| AIQ Score | 59/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $2.53B |
| P/E Ratio (TTM) | 22.76 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $2.15 |
| Revenue (quarter ended 2026-06-30) | $131.95M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 2.42 |
| Volume | 1.64M |
| 52-week range | $14.03-$72.71 |
| RSI 14 | 58.13 |
| 50-Day SMA | $56.27 |
| 200-Day SMA | $31.76 |
| Analyst Price Target | $52.12 |
| Next Earnings | Oct 29, 2026 |
CDNACareDx, Inc
Healthcare / Medical - Diagnostics & Research
Low Priority
Above Peers
Latest quote
- Momentum68
- Value27
- Quality92
- Risk resilience39
- Sentiment—
CDNA Stock Analysis Summary
CareDx, Inc (CDNA) currently has an AIQ Score of 59/100, indicating a neutral setup. Quality is the strongest factor at 92/100. Value is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, CDNA has AIQ Score of 59/100 with Quality base of 92/100 and fading Value at 27/100. Wait for component alignment before adding exposure.
Quality (92/100) leads while Value (27/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 2.23% stock move · CDNA classified in Medical - Diagnostics & Research.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is CDNA Bullish or Bearish Right Now?
CDNA currently has a neutral overall setup. Quality is the strongest factor at 92/100, while Value is weakest at 27/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 92/100.
- - Momentum is constructive at 68/100.
- - Price is +25.72% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (36 vs 4).
- - Value is the current constraint at 27/100.
- - Risk Resilience is weak at 39/100.
- - Analyst target implies -26.32% downside from the latest quote.
Current Consensus
CDNA's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 5 neutral, and 4 sell votes. CDNA's 14-day RSI is 58.13, which places the stock in a constructive momentum range. CDNA's beta is 2.42, indicating greater market sensitivity than the broad market.
What Changed in CDNA?
The largest recent change in CDNA is Momentum moving up by 2.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the CDNA Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
CDNA Decision Framework
Public evidence layers, setup checks, and risk context for CareDx, Inc.
CareDx, Inc (CDNA) Stock Analysis
CareDx, Inc has an AIQ Score of 59/100 in a Neutral regime. Quality is strongest at 92/100. Beta is 2.38, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | CDNA is in a Neutral AIQ regime with score 59/100. |
| Signal Conflict | The primary conflict is that quality leads at 92/100 while value lags at 27/100. |
| Factor Evidence | Momentum 68/100 · Value 27/100 · Quality 92/100 · Risk 39/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 92/100.
Momentum is 68/100 and RSI (14) is 58.1.
CDNA is in a Neutral regime at 59/100.
Risk factor is 39/100 with beta 2.38 and annual volatility 73.07%.
Current conflict: quality leads at 92/100 while value lags at 27/100.
CDNA Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
CDNA Fundamentals
CDNA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
CDNA Technical Analysis
CDNA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
CDNA Stock Catalysts
Track CDNA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
CDNA Dividend Analysis
CDNA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
CDNA Financial Data
CDNA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
CDNA Risk Analysis
CDNA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
CDNA Stock News
CDNA stock news, market tone, recent headlines, and catalyst context.
CDNA vs Life Sciences / Tools / CRO Peers
Current peer cohort: CDNA · CERT · CLVT · DHR · EFX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| CDNA Current stock | 59/100 | 27/100 | 68/100 | 39/100 | 2.4 | 73.07% | Current |
| CERT Certara | 56/100 | 53/100 | 69/100 | 49/100 | -0.08 | 59.65% | CDNA vs CERT |
| CLVT Clarivate | 54/100 | 75/100 | 53/100 | 31/100 | -0.64 | 76.42% | CDNA vs CLVT |
| DHR Danaher | 57/100 | 37/100 | 80/100 | 59/100 | 0.4 | 30.82% | CDNA vs DHR |
| EFX Equifax | 57/100 | 53/100 | 87/100 | 36/100 | -0.57 | 40.68% | CDNA vs EFX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 21, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts4 recent quarterly periods are available for review.
Checked Oct 21, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching CDNA
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for CDNA
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
CDNA Stock FAQ
What is CDNA stock price today?
CareDx, Inc's current stock price is $70.74. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is CDNA bullish or bearish right now?
CDNA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is CDNA's market cap?
CDNA's market cap is $2.53B based on the latest completed market-close snapshot from Oct 21, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is CDNA's current P/E ratio?
CDNA's current P/E ratio is 22.76 based on the latest completed market-close snapshot from Oct 21, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is CDNA's RSI?
CDNA's 14-day RSI is 58.13 based on the latest completed market-close snapshot from Oct 21, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is CDNA above its 50-day and 200-day moving averages?
CDNA is 25.72% from its 50-day SMA and 122.72% from its 200-day SMA based on the latest completed market-close snapshot from Oct 21, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is CDNA's next earnings date?
CDNA's next earnings date is currently listed as Oct 29, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does CDNA pay a dividend?
CDNA's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 21, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.